Ignite Creation Date:
2024-05-05 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00464087
Status:
COMPLETED
Last Update Posted:
2013-08-01
First Post:
2007-04-19
Brief Title:
Switching From Fondaparinux to Bivalirudin or Unfractionated Heparin in ACS Patients Undergoing PCI
Sponsor:
Medstar Health Research Institute
Organization:
Medstar Health Research Institute
Study Overview
Official Title:
Switching From Arixtra Fondaparinux to Angiomax Bivalirudin or Unfractionated Heparin in Patients With Acute Coronary Syndromes ACS Without ST-segment Elevation Undergoing Percutaneous Coronary Intervention PCI SWITCH III
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SWITCHIII
Brief Summary:
The primary objective of this clinical trial is to evaluate safety of switching from fondaparinux to either unfractionated heparin or bivalirudin for patients experiencing acute coronary syndrome undergoing percutaneous coronary angioplasty
Detailed Description:
This is a prospective open label randomized multi-center registry One hundred patients who received fondaparinux within the 24 hours prior to presentation to the coronary catheterization lab and who are suitable for percutaneous coronary intervention The patients will be randomized in a 11 fashion to either unfractionated heparin or bivalirudin during the angioplasty All patients will be followed throughout the duration of the hospital stay
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None